MRI analysis of mGluR5 and mGluR1 antagonists, MTEP and R214127 in the cerebral forebrain of awake, conscious rats.
Metabotropic glutamate receptors mGluR5 and mGluR1 mediate key neuropsychiatric functions in health and disease and their antagonists hold promise to treat anxiety, depression, inflammation, and neuropathic pain. Pharmacological magnetic resonance imaging (phMRI) using a functional MRI approach in awake, conscious rodents can determine the activities of receptor ligands without the potential interference of anesthetics and independent of the specific biochemical mechanism of action of the candidate molecule. In this study we determined the neuronal activation patterns of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) and 1-(3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl0-2phenyl-1-ethanone (R214127), antagonists of mGluR5 and mGluR1 receptors by phMRI. We found that MTEP and R214127 activated specific primary somatosensory, piriform, entorhinal and motor cortices and the caudateputamen each to a different extent and in partly overlapping manners. Additional analysis of the activation data indicated that these brain regions and their connections are involved in mediating neuropathic pain and also, reward and olfaction. Using awake, conscious animals in phMRI can be a useful approach in characterizing candidate mGluR5 and mGlR1 antagonists also allowing a more direct comparison of animal and human phMRI studies.
Neuronomix Inc., 5620 Sonoma Rd., Bethesda, MD 20817, USA.
Laszlo
L
Simon
Joseph
J
Toth
Levente
L
Molnar
Denes V
DV
Agoston
D000818:Animals; D054022:Cerebrum / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D003243:Consciousness / Q000187:drug effects / Q000502:physiology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D008297:Male; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism; D011714:Pyrans / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*; D051381:Rats; D020318:Rats, Long-Evans; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors* / Q000502:physiology; D013844:Thiazoles / Q000494:pharmacology*; D014851:Wakefulness / Q000187:drug effects / Q000502:physiology
C472365:3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine; D018691:Excitatory Amino Acid Antagonists; C578935:GRM5 protein, human; C578937:Grm5 protein, rat; D011714:Pyrans; D011725:Pyridines; D011804:Quinolines; C473784:R 214127; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate; D013844:Thiazoles; C104077:metabotropic glutamate receptor type 1